Self-tolerance of natural killer cells
Top Cited Papers
- 1 July 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 6 (7) , 520-531
- https://doi.org/10.1038/nri1863
Abstract
Natural killer (NK) cells, similar to other lymphocytes, acquire tolerance to self. This means that NK cells have the potential to attack normal self cells but that there are mechanisms to ensure that this does not usually occur. Self-tolerance is acquired by NK cells during their development, but the underlying molecular and cellular mechanisms remain poorly understood. Recent studies have produced important new information about NK-cell self-tolerance. Here, we review the evidence for and against possible mechanisms of NK-cell self-tolerance, with an emphasis on the role of MHC-specific receptors.Keywords
This publication has 103 references indexed in Scilit:
- The DNA damage pathway regulates innate immune system ligands of the NKG2D receptorNature, 2005
- Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirusNature Immunology, 2005
- Immune functions encoded by the natural killer gene complexNature Reviews Immunology, 2003
- A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunityEuropean Journal of Immunology, 2003
- MHC-dependent shaping of the inhibitory Ly49 receptor repertoire on NK cells: evidence for a regulated sequential modelEuropean Journal of Immunology, 2001
- Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated CytolysisAnnual Review of Immunology, 2001
- Recognition of the Class Ib Molecule Qa-1b by Putative Activating Receptors Cd94/Nkg2c and Cd94/Nkg2e on Mouse Natural Killer CellsThe Journal of Experimental Medicine, 1999
- Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICAScience, 1999
- NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate CytokinesAnnual Review of Immunology, 1999
- Activity and Phenotype of Natural Killer Cells in Peptide Transporter (TAP)-deficient Patients (Type I Bare Lymphocyte Syndrome)The Journal of Experimental Medicine, 1998